SELLAS Life Sciences Group, Inc.
- SLS
- NASDAQ
- Biotechnology
- Cancer Immunotherapy
- Peptide Vaccine
$10.49
Today +5.11%Quote Oct 19, 2026, 08:00 PM UTC
−8.70%over the last month
Max drawdown −19.6%From 1-month high −15.5%3 months −18.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About SELLAS Life Sciences
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
13
Market value
$2.12B
Quote Oct 19
Analyst target
$35.00
+233.7% from here
Floor
$8.92
15.0% below price
Resistance
$10.68
1.8% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about SLSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free